Skip to Content

Drug Patches Advance

Radiowave removal of skin aids delivery of medication.
November 1, 2003

For the millions of diabetics and other patients who need to self-inject drugs daily with painful needles, reliable skin patch devices-similar to the ones ex-smokers use to get their nicotine fix-would be a great relief. The trick is finding ways to push large-molecule drugs, like insulin and human growth hormone, through the skin’s oily top layers. An Israeli company believes it has a promising solution: radio waves.

TransPharma Medical of Yehud, Israel, has developed a handheld device that administers a blast of radio frequency energy to scrape away the top layer of skin cells. This produces channels about 50 micrometers wide that allow drugs from a patch to work their way into the bloodstream. “Of the methods used to open up channels through the skin to allow bigger molecules to be delivered, this company’s approach sounds the most promising,” says Gordon Flynn, professor of pharmaceutical science at the University of Michigan. That’s because the device-which has met with success in initial studies-opens pores for a whole day with minimum discomfort, sterilizes them, and adjusts for different skin types, Flynn says.

Still, TransPharma hasn’t proven its technology in human trials. Chief executive officer Daphna Heffetz says that within a few months, the company will begin clinical trials of a patch for people suffering from human-growth-hormone deficiencies. The company is conducting studies with four pharmaceutical companies to determine the feasibility of the approach with insulin and other drugs. “It looks interesting, but it is still early stage,” says Samir Mitragotri, a chemical engineer at the University of California, Santa Barbara, and a cofounder of Sontra Medical of Franklin, MA.

There’s plenty of competition. Sontra, for example, is developing an approach that uses ultrasound. “There is a place for more than one technology in the market. I think each viable technology will find its niche,” says Mitragotri. Whichever versions succeed, they could create a $5.7 billion market by 2009 in the U.S. alone, says Ajit Baid, analyst at the research firm Frost and Sullivan.

<

Leading Approaches to through-the-Skin Drug Delivery
Company
Technology
Status
Altea Therapeutics (Atlanta, GA) Electrical pulse that turns to heat to create micropores through skin Patches for osteoporosis, pain medication, and insulin in preliminary trials
Alza
(Mountain View, CA)
Low-level electric current that opens up pores In final phase of tests for fentanyl, a drug used to treat postoperative pain
Sontra Medical
(Franklin, MA)
Ultrasound used to open up pores In development for growth hormones; pain patches could be ready by 2006
TransPharma Medical
(Yehud, Israel)
Radio frequency energy that creates microchannels through the top
layer of skin
Preliminary human trials for human growth hormone; feasibility studies with four pharmaceutical companies

Keep Reading

Most Popular

still from Embodied Intelligence video
still from Embodied Intelligence video

These weird virtual creatures evolve their bodies to solve problems

They show how intelligence and body plans are closely linked—and could unlock AI for robots.

conceptual illustration showing various women&#039;s faces being scanned
conceptual illustration showing various women&#039;s faces being scanned

A horrifying new AI app swaps women into porn videos with a click

Deepfake researchers have long feared the day this would arrive.

protein structures
protein structures

DeepMind says it will release the structure of every protein known to science

The company has already used its protein-folding AI, AlphaFold, to generate structures for the human proteome, as well as yeast, fruit flies, mice, and more.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.